Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: regadenoson

« Back to Dashboard
Regadenoson is the generic ingredient in one branded drug marketed by Astellas and is included in one NDA. There are fifteen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

This ingredient has seventy-seven patent family members in twenty-four countries.

There are five drug master file entries for regadenoson. One supplier is listed for this compound.

Summary for Generic Name: regadenoson

Tradenames:1
Patents:15
Applicants:1
NDAs:1
Drug Master File Entries: see list5
Suppliers / Packaging: see list1

Pharmacology for Ingredient: regadenoson

Clinical Trials for: regadenoson

Regadenoson to Achieve Maximal Hyperemia for Fractional Flow Reserve in the Catheterization Lab
Status: Recruiting Condition: Coronary Artery Disease

Regadenoson and Adenosine
Status: Completed Condition: Coronary Artery Disease

Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Completed Condition: Coronary Artery Disease; Type 1 Diabetes Mellitus

A Phase II Trial of Regadenoson in Sickle Cell Anemia
Status: Recruiting Condition: Sickle Cell Anemia

Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation
Status: Recruiting Condition: Myocardial Blood Flow Reserve

Regadenoson Real Time Perfusion Imaging Trial-Optison
Status: Recruiting Condition: Coronary Artery Disease; Myocardial Perfusion Abnormalities

Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson
Status: Completed Condition: Ischemic Heart Disease

Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress
Status: Completed Condition: Coronary Artery Disease

ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Status: Completed Condition: Coronary Artery Disease

ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Status: Completed Condition: Coronary Artery Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYes7,655,637<disabled>YY<disabled>
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYes8,183,226<disabled><disabled>
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYes9,045,519<disabled>Y<disabled>
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYes8,470,801<disabled><disabled>
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYes7,582,617<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: regadenoson

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,278,435N-pyrazole A2A receptor agonists<disabled in preview>
8,071,566Methods of coronary imaging<disabled in preview>
8,906,878Myocardial perfusion imaging methods and compositions<disabled in preview>
8,268,988Process for preparing an A2A-adenosine receptor agonist and its polymorphs<disabled in preview>
7,732,595Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: regadenoson

Country Document Number Publication Date
TaiwanI230161Apr 01, 2005
European Patent Office2581381Oct 30, 2013
South Africa200703229Jul 29, 2009
Canada2671940Aug 30, 2001
Germany60007127Sep 16, 2004
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc